Peer-influenced content. Sources you trust. No registration required. This is HCN.
Conexiant
Early trials suggest red‑light therapy may slow pediatric myopia progression, but unanswered questions around long‑term retinal safety and clinical positioning remain.
Ophthalmology April 20th 2026
Psych Congress NP Institute
“These findings support AMPA receptors as a clinically relevant treatment target in MDD.” – Samantha Yohn, PhD, Neurocrine Biosciences, Psych Congress NP Institute, 2026
Psychiatry April 1st 2026
Cleveland Clinic Journal of Medicine (CCJM)
“Pelacarsen lowered lipoprotein(a) to less than 50 mg/dL in 98% of participants, but levels rebounded after 16 weeks.”
Cardiology December 3rd 2025
News Medical
Methylene blue’s ability to penetrate the blood-brain barrier while reducing oxidative stress and promoting Nrf2 expression presents a novel therapeutic pathway for neurodegenerative disorders that warrants further investigation despite limited clinical evidence.
Emergency Medicine April 30th 2025